JP2025532676A - 痙縮治療のためのｎｇｆ - Google Patents

痙縮治療のためのｎｇｆ

Info

Publication number
JP2025532676A
JP2025532676A JP2025517344A JP2025517344A JP2025532676A JP 2025532676 A JP2025532676 A JP 2025532676A JP 2025517344 A JP2025517344 A JP 2025517344A JP 2025517344 A JP2025517344 A JP 2025517344A JP 2025532676 A JP2025532676 A JP 2025532676A
Authority
JP
Japan
Prior art keywords
ngf
mutant protein
seq
tbi
spasticity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025517344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025532676A5 (enExample
Inventor
アレグレッティ，マルチェッロ
アラミニ，アンドレア
ブランドリーニ，ローラ
カッターニ，フランカ
マンテルリ，フラビオ
Original Assignee
ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ filed Critical ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Publication of JP2025532676A publication Critical patent/JP2025532676A/ja
Publication of JP2025532676A5 publication Critical patent/JP2025532676A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2025517344A 2022-09-23 2023-09-25 痙縮治療のためのｎｇｆ Pending JP2025532676A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22197562.6 2022-09-23
EP22197562.6A EP4342485A1 (en) 2022-09-23 2022-09-23 Ngf for the treatment of spasticity
PCT/EP2023/076387 WO2024062135A1 (en) 2022-09-23 2023-09-25 Ngf for the treatment of spasticity

Publications (2)

Publication Number Publication Date
JP2025532676A true JP2025532676A (ja) 2025-10-01
JP2025532676A5 JP2025532676A5 (enExample) 2026-04-28

Family

ID=83438536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025517344A Pending JP2025532676A (ja) 2022-09-23 2023-09-25 痙縮治療のためのｎｇｆ

Country Status (7)

Country Link
EP (2) EP4342485A1 (enExample)
JP (1) JP2025532676A (enExample)
CN (1) CN120239610A (enExample)
AU (1) AU2023345675A1 (enExample)
CA (1) CA3266315A1 (enExample)
IL (1) IL319010A (enExample)
WO (1) WO2024062135A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0994188B1 (de) 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
ES2966133T3 (es) * 2016-03-18 2024-04-18 Staidson Beijing Biopharmaceuticals Co Ltd Proteína de fusión que comprende el factor de crecimiento nervioso y método de preparación y uso de la misma
IT201600112420A1 (it) * 2016-11-08 2018-05-08 Univ Cattolica Del Sacro Cuore Nuova formulazione per via intranasale
MA52351B1 (fr) 2018-04-27 2026-04-30 Chiesi Farmaceutici S.P.A. Production de facteur de croissance nerveuse (ngf) et de ses mutéines
ES2992180T3 (es) * 2019-09-17 2024-12-10 Chiesi Farm Spa Mutante de NGF para su uso en el tratamiento o prevención de trastornos oftálmicos
WO2022105847A1 (en) * 2020-11-19 2022-05-27 Staidson (Beijing) Biopharmaceuticals Co. , Ltd. Long-acting nerve growth factor polypeptides and uses thereof

Also Published As

Publication number Publication date
EP4590324A1 (en) 2025-07-30
IL319010A (en) 2025-04-01
EP4342485A1 (en) 2024-03-27
AU2023345675A1 (en) 2025-03-06
CN120239610A (zh) 2025-07-01
CA3266315A1 (en) 2024-03-28
WO2024062135A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
JP4154237B2 (ja) 異痛症および他の種々のタイプの慢性疼痛または幻肢痛を治療するための化合物のペプチドクラスの新規使用
US12503501B2 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
Zhang et al. Enriched environment promotes post-stroke neurogenesis through NF-κB-mediated secretion of IL-17A from astrocytes
US20180250365A1 (en) Acth for treatment of amyotrophic lateral sclerosis
JP2838073B2 (ja) 痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物
CN101288768A (zh) 用于治疗渐进神经退化症的医药组合物
CN112533676A (zh) 用于抑制cgrp的神经毒素
WO2009049215A1 (en) Methods to reduce the effects of sleep deprivation
EP2640410B1 (de) Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
Westin et al. Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy
Leung et al. Cholinergic modulation of general anesthesia
AU2023345675A1 (en) Ngf for the treatment of spasticity
Huang et al. The macroscopic and microscopic effect of low-frequency whole-body vibration after cerebral ischemia in rats
US12246058B2 (en) Methods and compositions for treating pain
Morishita et al. Subacute intranasal oxytocin improves neurological recovery after ischemic stroke
KR20190142404A (ko) 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법
JP2022544028A (ja) レボドパ誘発性ジスキネジアの治療または進行抑制用の薬学組成物
García del Barco et al. Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model
KR20260049790A (ko) 신경 손상 복구 제품의 제조에서의 2가 금속 락테이트의 용도
US10987411B1 (en) Treatment of chronic obstructive pulmonary disease using botulinum toxin
KR20230071072A (ko) 보툴리눔 독소 조성물
US9896488B2 (en) Protamine in treatment of neuronal injuries
KR20080059229A (ko) 정상적 호흡 리듬의 회복을 위한 ｓ-니트로소티올계 조합제약 생성물
Subramanian Restoration of motor and non-motor functions by neurotrophic factors in nonhuman primates with dopamine depletion
Cairns et al. Tooth pulp–and facial hair mechanoreceptor–evoked responses of trigeminal sensory neurons are attenuated during ketamine anesthesia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260420